Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00242593
Status:
UNKNOWN
Last Update Posted:
2011-08-05
First Post:
2005-10-19
Brief Title:
Rosiglitazone Effects on Cognition for Adults in Later Life
Sponsor:
University of Washington
Organization:
University of Washington
Study Overview
Official Title:
The Effects of Rosiglitazone on Cognition in Patients With MCI
Status:
UNKNOWN
Status Verified Date:
2011-08
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RECALL
Brief Summary:
The purpose of this study is to determine the effects of the insulin-sensitizing medication rosiglitazone on attention and memory skills in older adults with mild cognitive impairment MCI The study also will examine the effects of this medication on brain structures that support memory and other thinking abilities and on biological markers associated with inflammation insulin resistance and cardiovascular disease
Detailed Description:
The study will examine the effects of the insulin-sensitizing agent rosiglitazone on learning and memory for 120 patients diagnosed with MCI Participants will be randomized to an 18-month trial of rosiglitazone or placebo followed by a 2-month washout period At screening and at treatment month 18 all participants will undergo an oral glucose tolerance test OGTT to estimate pre- and post- treatment insulin sensitivity and β-cell function Cognitive measures and blood samples for biochemical assays will be obtained at baseline treatment months 6 12 and 18 and washout two months after completing treatment
During treatment participants will have safety labs drawn and receive physical assessment of any adverse events changes in health status or changes in medication initially these visits will be done at weeks 2 and 4 and then every three months For months in which a safety visit is not scheduled telephone monitoring to assess any health concerns will be conducted
All participants enrolled in the primary study will be approached to participate in an MRI substudy patients will undergo serial brain MRI before treatment and following 18 months of rosiglitazone or placebo using three-dimensional T1-weighted images Comparison of MCI patients receiving rosiglitazone and placebo will be conducted to determine whether the rate of medial temporal lobe MTL and whole brain atrophy is altered following treatment
During treatment participants will have safety labs drawn and receive physical assessment of any adverse events changes in health status or changes in medication initially these visits will be done at weeks 2 and 4 and then every three months For months in which a safety visit is not scheduled telephone monitoring to assess any health concerns will be conducted
All participants enrolled in the primary study will be approached to participate in an MRI substudy patients will undergo serial brain MRI before treatment and following 18 months of rosiglitazone or placebo using three-dimensional T1-weighted images Comparison of MCI patients receiving rosiglitazone and placebo will be conducted to determine whether the rate of medial temporal lobe MTL and whole brain atrophy is altered following treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1R01AG025502-01A1 | NIH | None | httpsreporternihgovquickSearch1R01AG025502-01A1 |